FIG. 1A

```
    ATGTGGAAATGGATACTGACACATTGTGCCTCAGCCTTTCCCCAGCTGCCCGGCTGCTGC
1   ---------+---------+---------+---------+---------+---------+ 60
    TACACCTTTACCTATGACTGTGTAACACGGAGTCGGAAAGGGGTGGACGGGCCGACGACG

    M  W  K  W  I  L  L  T  H  C  A  S  A  F  P  H  L  P  G  C  C  -

    TGCTGCTGCTTTTTGTTGCTGTTCTTGGTGTCTTCCGTCCCTGTCACCTGCCAAGCCCTT
61  ---------+---------+---------+---------+---------+---------+ 120
    ACGACGACGAAAAACAACGACAAGAACCACAGAAGGCAGGGACAGTGGACGGTTCGGGAA

    C  C  C  F  L  L  L  F  L  V  S  S  V  P  V  T  C  Q  A  L  -

    GGTCAGGACATGGTGTCACCAGAGGCCACCAACTCTTCTTCCTCCTCCTTCTCCTCTCCT
121 ---------+---------+---------+---------+---------+---------+ 180
    CCAGTCCTGTACCACAGTGGTCTCCGGTGGTTGAGAAGAAGGAGGAGGAAGAGGAGAGGA

    G  Q  D  M  V  S  P  E  A  T  N  S  S  S  S  S  F  S  S  P  -

    TCCAGCGCGGGAAGGCATGTgCGGAGCTACAATCACCTTCAAGGAGATGTCCGCTGGAGA
181 ---------+---------+---------+---------+---------+---------+ 240
    AGGTCGCGCCCTTCCGTACAcGCCTCGATGTTAGTGGAAGTTCCTCTACAGGCGACCTCT

    S  S  A  G  R  H  V  R  S  Y  N  H  L  Q  G  D  V  R  W  R  -
```

MATCH WITH FIG. 1B

MATCH WITH FIG. 1A

FIG. 1B

```
     AAGCTATTCTCTTTCACCAAGTACTTTCTCAAGATTGAGAAGAACGGGAAGGTCAGCGGG
241  ---------+---------+---------+---------+---------+---------+ 300
     TTCGATAAGAGAAAGTGGTTCATGAAAGAGTTCTAACTCTTCTTGCCCTTCCAGTCGCCC

      K  L  F  S  F  T  K  Y  F  L  K  I  E  K  N  G  K  V  S  G  -

     ACCAAGAAGGAGAACTGCCCGTACAGCATCCTGGAGATAACATCAGTAGAAATCGGAGTT
301  ---------+---------+---------+---------+---------+---------+ 360
     TGGTTCTTCCTCTTGACGGGCATGTCGTAGGACCTCTATTGTAGTCATCTTTAGCCTCAA

      T  K  K  E  N  C  P  Y  S  I  L  E  I  T  S  V  E  I  G  V  -

     GTTGCCGTCAAAGCCATTAACAGCAACTATTACTTAGCCATGAACAAGAAGGGGAAACTC
361  ---------+---------+---------+---------+---------+---------+ 420
     CAACGGCAGTTTCGGTAATTGTCGTTGATAATGAATCGGTACTTGTTCTTCCCCTTTGAG

      V  A  V  K  A  I  N  S  N  Y  Y  L  A  M  N  K  K  G  K  L  -

     TATGGCTCAAAAGAATTTAACAATGACTGTAAGCTGAAGGAGAGGATAGAGGAAAATGGA
421  ---------+---------+---------+---------+---------+---------+ 480
     ATACCGAGTTTTCTTAAATTGTTACTGACATTCGACTTCCTCTCCTATCTCCTTTTACCT

      Y  G  S  K  E  F  N  N  D  C  K  L  K  E  R  I  E  E  N  G  -
```

MATCH WITH FIG. 1C

MATCH WITH FIG. 1B

FIG. 1C

```
    TACAATACCTATGCATCATTTAACTGGCAGCATAATGGGAGGCAAATGTATGTGGCATTG
481 ---------+---------+---------+---------+---------+---------+ 540
    ATGTTATGGATACGTAGTAAATTGACCGTCGTATTACCCTCCGTTTACATACACCGTAAC

     Y  N  T  Y  A  S  F  N  W  Q  H  N  G  R  Q  M  Y  V  A  L  -

    AATGGAAAAGGAGCTCCAAGGAGAGGACAGAAAACACGAAGGAAAAACACCTCTGCTCAC
541 ---------+---------+---------+---------+---------+---------+ 600
    TTACCTTTTCCTCGAGGTTCCTCTCCTGTCTTTTGTGCTTCCTTTTTGTGGAGACGAGTG

     N  G  K  G  A  P  R  R  G  Q  K  T  R  R  K  N  T  S  A  H  -

    TTTCTTCCAATGGTGGTACACTCATAG
601 ---------+---------+------- 627
    AAAGAAGGTTACCACCATGTGAGTATC
     F  L  P  M  V  V  H  S  *
```

FIG. 2A

```
      1                                                        50
FGF4  MS.GPGTAAV ALLPAVLLAL LA........ .PWAGRGGAA APTAPNGTLE
FGF6  MSRGAGRLQG TLWALVFLGI LV........ .GMVVPSPAG TR.ANNTLLD
FGF5  .......MSL SFLLLLFFSH LILSAWAHGE KRLAPKGQPG PAATDRNPIG
FGF1  .......... .......... .......... .......... ..........
FGF2  .......... .......... .......... .......... ..........
FGF9  .......... .......... .......... ..MAPLGEVG NYFGVQDAVP
FGF7  .......... ......MHKW ILTWILPTLL .....YRSCF HIICLVGTIS
KGF2  .......... ......MWKW ILTHCASAFP HLPGCCCCCF LLLFLVSSVP
FGF3  .......... .......... .......... .......MGL IWLLLLSLLE
FGF8  MGSPRSALSC LLLHLLVLCL QAQVRSAAQK RGPGAGNPAD TLGQGHEDRP

      51                                                      100
FGF4  AELERRWESL VALSLARLPV AA..QPKEAA VQSGAGDY.. ...LLGIKRL
FGF6  S...RGWGTL LSRSRAGLAG EI......AG VNWESG.Y.. ...LVGIKRQ
FGF5  SSSRQSSSSA MSSSSASSSP AASLGSQGSG LEQSSFQW.. ...SPSGRRT
FGF1  ......MAEG EITTFTALTE KFN...LPPG .......N.. ...YK...KP
FGF2  ......MAAG SITTLPALPE DGGSGAFPPG .......H.. ...FK...DP
FGF9  FGNVPVLPVD SPVLLSDHLG QSEAGGLPRG PAVTDLDH.. ...LKGILRR
FGF7  LACNDMTPEQ M...ATNVNC ......SSPE RHTRSYDY.. ...MEGGDIR
KGF2  VTCQALGQDM VSPEATNSSS SSFSSPSSAG RHVRSYNH.. ...LQ.GDVR
FGF3  PGWPAAGPGA .......... ...RLRRDAG GRGGVYEH.. ...L.GGAPR
FGF8  FGQRSRAGKN FTNPAPNYPE EGSKEQRDSV LPKVTQRHVR EQSLVTDQLS
```

MATCH WITH FIG. 2B

MATCH WITH FIG. 2A

FIG. 2B

```
      101                                                 150
FGF4  RRL.....YC NVGIGFHLQA LPDGRIGGAH ADT.RDSLLE LSPVERGV.V
FGF6  RRL.....YC NVGIGFHLQV LPDGRISGTH EEN.PYSLLE ISTVERGV.V
FGF5  GSL.....YC RVGIGFHLQI YPDGKVNGSH EAN.MLSVLE IFAVSQGI.V
FGF1  KLL.....YC SNG.GHFLRI LPDGTVDGTR DRSDQHIQLQ LSAESVGE.V
FGF2  KRL.....YC KNG.GFFLRI HPDGRVDGVR EKSDPHIKLQ LQAEERGV.V
FGF9  RQL.....YC R.T.GFHLEI FPNGTIQGTR KDHSRFGILE FISIAVGL.V
FGF7  VRR.....LF CRT.QWYLRI DKRGKVKGTQ EMKNNYNIME IRTVAVGI.V
KGF2  WRK.....LF SFT.KYFLKI EKNGKVSGTK KENCPYSILE ITSVEIGV.V
FGF3  RRK.....LY CAT.KYHLQL HPSGRVNGSL .ENSAYSILE ITAVEVGI.V
FGF8  RRLIRTYQLY SRTSGKHVQV LANKRINAMA EDGDPFAKLI VETDTFGSRV

      151                                                 200
FGF4  SIFGVASRFF VAMSSKGKLY G.SPFFTDEC TFKEILLPNN YNAYESYKY
FGF6  SLFGVRSALF VAMNSKGRLY A.TPSFQEEC KFRETLLPNN YNAYESDL
FGF5  GIRGVFSNKF LAMSKKGKLH A.SAKFTDDC KFRERFQENS YNTYASA
FGF1  YIKSTETGQY LAMDTDGLLY G.SQTPNEEC LFLERLEENH YNTYIS
FGF2  SIKGVCANRY LAMKEDGRLL A.SKCVTDEC FFFERLESNN YNTY
FGF9  SIRGVDSGLY LGMNEKGELY G.SEKLTQEC VFREQFEENW YNT
FGF7  AIKGVESEFY LAMNKEGKLY A.KKECNEDC NFKELILENH YNRLYR
KGF2  AVKAINSNYY LAMNKKGKLY G.SKEFNNDC KLKERIEENG QNAKY.
FGF3  AIRGLFSGRY LAMNKRGRLY A.SEHYSAEC EFVERIHELG
FGF8  RVRGAETGLY ICMNKKGKLI AKSNGKGKDC VFTEIVLEN
```

MATCH WITH FIG. 2C

MATCH WITH FIG. 2B

FIG. 2C

```
      201                                                          250
FGF4  .......... GM......FI ALSKNGKTKK G..NRVSPTM KVTHFLPRL.
FGF6  .......... GT......YI ALSKYGRVKR G..SKVSPIM TVTHFLPRI.
FGF5  .......... TEKTGREWYV ALNKRGKAKR GCSPRVKPQH ISTHFLPRFK
FGF1  .......... ...AEKNWFV GLKKNGSCKR G..PRTHYGQ KAILFLPLPV
FGF2  .......... ...T..SWYV ALKRTGQYKL G..SKTGPGQ KAILFLPMSA
FGF9  HV........ ..DTGRRYYV ALNKDGTPRE G..TRTKRHQ KFTHFLPRPV
FGF7  .......AKW THNGGEM.FV ALNQKGIPVR G..KKTKKEQ KTAHFLPMAI
KGF2  .......FNW QHNGRQM.YV ALNGKGAPRR G..QKTRRKN TSAHFLPMVV
FGF3  TVSSTPGARR QPSAERLWYV SVNGKGRPRR G..FKTRRTQ KSSLFLPRVL
FGF8  .......... .....EGWYM AFTRKGRPRK G..SKTRQHQ REVHFMKRLP

      251                                                          300
FGF4  .......... .......... .......... .......... ..........
FGF6  .......... .......... .......... .......... ..........
FGF5  QSEQPELSFT VTVPEKKNPP SPIKSKIPLS APRKNTNSVK ..........
FGF1  SSD....... .......... .......... .......... YRLKFRFG..
FGF2  KS........ .......... .......... .......... ..........
FGF9  DPDKVPELYK DILSQS.... .......... .......... ..........
FGF7  T......... .......... .......... .......... ..........
KGF2  HS........ .......... .......... .......... ..........
FGF3  DHRDHEMVRQ LQSGLPRPPG KGVQPRRRRQ KQSPDNLEPS ..........
FGF8  RGHHTTEQSL RFEFLNYPPF TRSLRGSQRT WAPEPR.... HVQASRLGSQ
```

MATCH WITH FIG. 2D

FIG. 2D

MATCH WITH FIG. 2C

	301
FGF4	......
FGF6	......
FGF5	......
FGF1	......
FGF2	......
FGF9	......
FGF7	......
KGF2	......
FGF3	LEASAH
FGF8	......

Figure 3A

GGAATTCCGG GAAGAGAGGG AAGAAAACAA CGGCGACTGG GCAGCTGCCT CCACTTCTGA 60

CAACTCCAAA GGGATATACT TGTAGAAGTG GCTCGCAGGC TGGGGCTCCG CAGAGAGAGA 120

CCAGAAGGTG CCAACCGCAG AGGGGTGCAG ATATCTCCCC CTATTCCCCA CCCCACCTCC 180

CTTGGGTTTT GTTCACCGTG CTGTCATCTG TTTTTCAGAC CTTTTTGGCA TCTAACATGG 240

TGAAGAAAGG AGTAAAGAAG AGAACAAAGT AACTCCTGGG GGAGCGAAGA GCGCTGGTGA 300

CCAACACCAC CAACGCCACC ACCAGCTCCT GCTGCTGCGG CCACCCACGT CCACCATTTA 360

CCGGGAGGCT CCAGAGGCGT AGGCAGCGGA TCCGAGAAAG GAGCGAGGGG AGTCAGCCGG 420

CTTTTCCGAG GAGTTATGGA TGTTGGTGCA TTCACTTCTG GCCAGATCCG CGCCCAGAGG 480

GAGCTAACCA GCAGCCACCA CCTCGAGCTC TCTCCTTGCC TTGCATCGGG TCTTACCCTT 540

CCAGTATGTT CCTTCTGATG AGACAATTTC CAGTGCCGAG AGTTTCAGTA CA ATG 595
Met

TGG AAA TGG ATA CTG ACA CAT TGT GCC TCA GCC TTT CCC CAC CTG CCC 643
Trp Lys Trp Ile Leu Thr His Cys Ala Ser Ala Phe Pro His Leu Pro

GGC TGC TGC TGC TGC TGC TTT TTG TTG CTG TTC TTG GTG TCT TCC GTC 691
Gly Cys Cys Cys Cys Cys Phe Leu Leu Leu Phe Leu Val Ser Ser Val

CCT GTC ACC TGC CAA GCC CTT GGT CAG GAC ATG GTG TCA CCA GAG GCC 739
Pro Val Thr Cys Gln Ala Leu Gly Gln Asp Met Val Ser Pro Glu Ala

ACC AAC TCT TCT TCC TCC TCC TTC TCC TCT CCT TCC AGC GCG GGA AGG 787
Thr Asn Ser Ser Ser Ser Ser Phe Ser Ser Pro Ser Ser Ala Gly Arg

CAT GTG CGG AGC TAC AAT CAC CTT CAA GGA GAT GTC CGC TGG AGA AAG 835
His Val Arg Ser Tyr Asn His Leu Gln Gly Asp Val Arg Trp Arg Lys

CTA TTC TCT TTC ACC AAG TAC TTT CTC AAG ATT GAG AAG AAC GGG AAG 883
Leu Phe Ser Phe Thr Lys Tyr Phe Leu Lys Ile Glu Lys Asn Gly Lys

GTC AGC GGG ACC AAG AAG GAG AAC TGC CCG TAC AGC ATC CTG GAG ATA 931
Val Ser Gly Thr Lys Lys Glu Asn Cys Pro Tyr Ser Ile Leu Glu Ile

ACA TCA GTA GAA ATC GGA GTT GTT GCC GTC AAA GCC ATT AAC AGC AAC 979
Thr Ser Val Glu Ile Gly Val Val Ala Val Lys Ala Ile Asn Ser Asn

TAT TAC TTA GCC ATG AAC AAG AAG GGG AAA CTC TAT GGC TCA AAA GAA 1027
Tyr Tyr Leu Ala Met Asn Lys Lys Gly Lys Leu Tyr Gly Ser Lys Glu

TTT AAC AAT GAC TGT AAG CTG AAG GAG AGG ATA GAG GAA AAT GGA TAC 1075
Phe Asn Asn Asp Cys Lys Leu Lys Glu Arg Ile Glu Glu Asn Gly Tyr

Figure 3B

AAT ACC TAT GCA TCA TTT AAC TGG CAG CAT AAT GGG AGG CAA ATG TAT 1123
Asn Thr Tyr Ala Ser Phe Asn Trp Gln His Asn Gly Arg Gln Met Tyr

GTG GCA TTG AAT GGA AAA GGA GCT CCA AGG AGA GGA CAG AAA ACA CGA 1171
Val Ala Leu Asn Gly Lys Gly Ala Pro Arg Arg Gly Gln Lys Thr Arg

AGG AAA AAC ACC TCT GCT CAC TTT CTT CCA ATG GTG GTA CAC TCA 1216
Arg Lys Asn Thr Ser Ala His Phe Leu Pro Met Val Val His Ser

TAGAGGAAGG CAACGTTTGT GGATGCAGTA AAACCAATGG CTCTTTTGCC AAGAATAGTG 1276
GATATTCTTC ATGAAGACAG TAGATTGAAA GGCAAAGACA CGTTGCAGAT GTCTGCTTGC 1336
TTAAAAGAAA GCCAGCCTTT GAAGGTTTTT GTATTCACTG CTGACATATG ATGTTCTTTT 1396
AATTAGTTCT GTGTCATGTC TTATAATCAA GATATAGGCA GATCGAATGG GATAGAAGTT 1456
ATTCCCAAGT GAAAAACATT GTGGCTGGGT TTTTTGTTGT TGTTGTCAAG TTTTTGTTTT 1516
TAAACCTCTG AGATAGAACT TAAAGGACAT AGAACAATCT GTTGAAAGAA CGATCTTCGG 1576
GAAAGTTATT TATGGAATAC GAACTCATAT CAAAGACTTC ATTGCTCATT CAAGCCTAAT 1636
GAATCAATGA ACAGTAATAC GTGCAAGCAT TTACTGGAAA GCACTTGGGT CATATCATAT 1696
GCACAACCAA AGGAGTTCTG GATGTGGTCT CATGGAATAA TTGAATAGAA TTTAAAAATA 1756
TAAACATGTT AGTGTGAAAC TGTTCTAACA ATACAAATAG TATGGTATGC TTGTGCATTC 1816
TGCCTTCATC CCTTTCTATT TCTTTCTAAG TTATTTATTT AATAGGATGT TAAATATCTT 1876
TTGGGGTTTT AAAGAGTATC TCAGCAGCTG TCTTCTGATT TATCTTTTCT TTTTATTCAG 1936
CACACCACAT GCATGTTCAC GACAAAGTGT TTTTAAAACT TGGCGAACAC TTCAAAAATA 1996
GGAGTTGGGA TTAGGGAAGC AGTATGAGTG CCCGTGTGCT ATCAGTTGAC TTAATTTGCA 2056
CTTCTGCAGT AATAACCATC AACAATAAAT ATGGCAATGC TGTGCCATGG CTTGAGTGAG 2116
AGATGTCTGC TATCATTTGA AAACATATAT TACTCTCGAG GCTTCCTGTC TCAAGAAATA 2176
GACCAGAAGG CCAAATTCTT CTCTTTCAAT ACATCAGTTT GCCTCCAAGA ATATACTAAA 2236
AAAAGGAAAA TTAATTGCTA AATACATTTA AATAGCCTAG CCTCATTATT TACTCATGAT 2296
TTCTTGCCAA ATGTCATGGC GGTAAAGAGG CTGTCCACAT CTCTAAAAAC CCTCTGTAAA 2356
TTCCACATAA TGCATCTTTC CCAAAGGAAC TATAAAGAAT TTGGTATGAA GCGCAACTCT 2416

Figure 3C

CCCAGGGGCT TAAACTGAGC AAATCAAATA TATACTGGTA TATGTGTAAC CATATACAAA 2476
AACCTGTTCT AGCTGTATGA TCTAGTCTTT ACAAAACCAA ATAAAACTTG TTTTCTGTAA 2536
ATTTAAAGAG CTTTACAAGG TTCCATAATG TAACCATATC AAAATTCATT TTGTTAGAGC 2596
ACGTATAGAA AAGAGTACAT AAGAGTTTAC CAATCATCAT CACATTGTAT TCCACTAAAT 2656
AAATACATAA GCCTTATTTG CAGTGTCTGT AGTGATTTTA AAAATGTAGA AAAATACTAT 2716
TTGTTCTAAA TACTTTTAAG CAATAACTAT AATAGTATAT TGATGCTGCA GTTTTATCTT 2776
CATATTTCTT GTTTTGAAAA AGCATTTTAT TGTTTGGACA CAGTATTTTG GTACAAAAAA 2836
AAAGACTCAC TAAATGTGTC TTACTAAAGT TTAACCTTTG GAAATGCTGG CGTTCTGTGA 2896
TTCTCCAACA AACTTATTTG TGTCAATACT TAACCAGCAC TTCCAGTTAA TCTGTTATTT 2956
TTAAAAATTG CTTTATTAAG AAATTTTTTG TATAATCCCA TAAAAGGTCA TATTTTTCCC 3016
ATTCTTCAAA AAAACTGTAT TTCAGAAGAA ACACATTTGA GGCACTGTCT TTTGGCTTAT 3076
AGTTTAAATT GCATTTCATC ATACTTTGCT TCCAACTTGC TTTTTGGCAA ATGAGATTAT 3136
AAAAATGTTT AATTTTTGTG GTTGGAATCT GGATGTTAAA ATTTAATTGG TAACTCAGTC 3196
TGTGAGCTAT AATGTAATGC ATTCCTATCC AAACTAGGTA TCTTTTTTTC CTTTATGTTG 3256
AAATAATAAT GGCACCTGAC ACATAGACAT AGACCACCCA CAACCTAAAT TAAATGTTTG 3316
GTAAGACAAA TACACATTGG ATGACCACAG TAACAGCAAA CAGGGCACAA ACTGGATTCT 3376
TATTTCACAT AGACATTTAG ATTACTAAAG AGGGCTATGT GTAAACAGTC ATCATTATAG 3436
TACTCAAGAC ACTAAAACAG CTTCTAGCCA AATATATTAA AGCTTGCAGA GGCCAAAAAT 3496
AGAAAACATC TCCCCTGTCT CTCCCACATT TCCCTCACAG AAAGACAAAA AACCTGCCTG 3556
GTGCAGTAGC TCACACCTGT AATCCCAGCA GTTTGGGAGA CTGTGGGAAG ATGGCTTGAG 3616
TCCAGGAGTT CTAGACAGGC CTGAGAAACC TAGTGAGACA TCCTTCTCTT AAACAAAACA 3676
AAACAAAACA AATGTAGCCA TGCGTGGTGG CATATACCTG TGGTCCCAAC TACTCAGGAG 3736
GCTGAAACGG AAGGATCTCT TGGGCCCCAG GAGTTTGAGG CTGCAGTGAG CTATAATCTT 3796
GCCATTGCAC TCCAGCCTGG GTGAAAAAGA GCCAGAAAGA AAGGAAAGAG AGAAAAGAGA 3856
AAAGAAAGAG AGAAAAGACA GAAAGACAGG AAGGAAGGAA GGAAGGAAGG AAGGAAGGAA 3916
GGAAGCAAGG AAAGAAGGAA GGAAGGAAAG AAGGGAGGGA AGGAAGGAGA GAGAAAGAAA 3976
GATTGTTTGG TAAGGAGTAA TGACATTCTC TTGCATTTAA AAGTGGCATA TTTGCTTGAA 4036

Figure 3D

ATGGAAATAG AATTCTGGTC CCTTTTGCAA CTACTGAAGA AAAAAAAAAG CAGTTTCAGC 4096

CCTGAATGTT GTAGATTTGA AAAAAAAAAA AAAAAAACTC GAGGGGGGGC CCGTACCCAA 4156

TTCGCCCTAT AGTGAGTCGT A 4177

Figure 4A



MWKWI LTHCASAFPHLPGCCCCCFLLLFLVSSVPVTCQALGQDMV
5 10 15 20 25 30 35 40
Alpha, Regions - Garnier-Robson
Alpha, Regions - Chou-Fasman
Beta, Regions - Garnier-Robson
Beta, Regions - Chou-Fasman
Turn, Regions - Garnier-Robson
Turn, Regions - Chou-Fasman
Coil, Regions - Garnier-Robson
Hydrophilicity Plot - Kyte-Doolittle
Hydrophobicity Plot - Hopp-Woods
Alpha, Amphipathic Regions - Eisenberg
Beta, Amphipathic Regions - Eisenberg
Flexible Regions - Karplus-Schulz
Antigenic Index - Jameson-Wolf
Surface Probability Plot - Emini

Figure 4C



K I EKNGKVSGTKKENCPYS I LE I TSVE I GVVAVKA I NSNYYLAMN
95
100
105
110
115
120
125
130
Alpha, Regions - Garnier-Robson
Alpha, Regions - Chou-Fasman
Beta, Regions - Garnier-Robson
Beta, Regions - Chou-Fasman
Turn, Regions - Garnier-Robson
Turn, Regions - Chou-Fasman
Coil, Regions - Garnier-Robson
Hydrophilicity Plot - Kyte-Doolittle
Hydrophobicity Plot - Hopp-Woods
Alpha, Amphipathic Regions - Eisenberg
Beta, Amphipathic Regions - Eisenberg
Flexible Regions - Karplus-Schulz
Antigenic Index - Jameson-Wolf
Surface Probability Plot - Emini

Figure 4B



SPEATNSSSSSFSSPSSAGRHVRSYNHLQGDVRWRKLFSFTKYFL
50 55 60 65 70 75 80 85
Alpha, Regions - Garnier-Robson
Alpha, Regions - Chou-Fasman
Beta, Regions - Garnier-Robson
Beta, Regions - Chou-Fasman
Turn, Regions - Garnier-Robson
Turn, Regions - Chou-Fasman
Coil, Regions - Garnier-Robson
Hydrophilicity Plot - Kyte-Doolittle
Hydrophobicity Plot - Hopp-Woods
Alpha, Amphipathic Regions - Eisenberg
Beta, Amphipathic Regions - Eisenberg
Flexible Regions - Karplus-Schulz
Antigenic Index - Jameson-Wolf
Surface Probability Plot - Emini

Figure 4D


KKGKLYGSKEFNNDCKLKERIEENGYNTYASFNWQHNGRQMYVAL
140
145
150
155
160
165
170
175
A
A
B
B
T
T
C
3.38
0
-3.33
3
0
-3.4
F
3.4
0
6
1
Alpha, Regions - Garnier-Robson
Alpha, Regions - Chou-Fasman
Beta, Regions - Garnier-Robson
Beta, Regions - Chou-Fasman
Turn, Regions - Garnier-Robson
Turn, Regions - Chou-Fasman
Coil, Regions - Garnier-Robson
Hydrophilicity Plot - Kyte-Doolittle
Hydrophobicity Plot - Hopp-Woods
Alpha, Amphipathic Regions - Eisenberg
Beta, Amphipathic Regions - Eisenberg
Flexible Regions - Karplus-Schulz
Antigenic Index - Jameson-Wolf
Surface Probability Plot - Emini

Figure 4E



.NGKGAPRRGQKTRRKNTSAHFLPMVVHS
185
190
195
200
205
A
A
B
B
T
T
C
F
Alpha, Regions - Garnier-Robson
Alpha, Regions - Chou-Fasman
Beta, Regions - Garnier-Robson
Beta, Regions - Chou-Fasman
Turn, Regions - Garnier-Robson
Turn, Regions - Chou-Fasman
Coil, Regions - Garnier-Robson
Hydrophilicity Plot - Kyte-Doolittle
Hydrophobicity Plot - Hopp-Woods
Alpha, Amphipathic Regions - Eisenberg
Beta, Amphipathic Regions - Eisenberg
Flexible Regions - Karplus-Schulz
Antigenic Index - Jameson-Wolf
Surface Probability Plot - Emini

Figure 5



% Wound Closure
80
75
70
65
60
55
50
45
40
35
30
25
20
15
10
5
0
3.8
p=0.0001
60.6
p=0.008
34.5
Buffer
n=5
KGF-2
4µg
n=5
KGF-2
40µg
n=5

Figure 6



% Wound Closure
80
75
70
65
60
55
50
45
40
35
30
25
20
15
10
5
0
p<0.0001
p=0.007
73.1
59.4
13.8
Buffer
n=5
KGF-2
4µg
n=5
KGF-2
40µg
n=5

Figure 7


Vehicle n=5
KGF-2 4μg n=5
KGF-2 40μg n=5
Wound Measure Area (sq. mm)
100
95
90
85
80
75
70
65
60
55
50
45
40
35
30
25
20
15
10
p=0.01
p=0.003
p=0.006
p=0.02
p=0.02
p=0.009
p=0.02
p=0.003
1
2
3
4
5
8
Days Postwounding

Figure 8



Vehicle n=5
KGF-2 4µg n=5
KGF-2 40µg n=5
Wound Measure Area (sq. mm)
100
95
90
85
80
75
70
65
60
55
50
45
40
35
30
25
20
15
10
p=0.02
p=0.03
p=0.004
p=0.04
p=0.01
p=0.02
p=0.02
p=0.002
1
2
3
4
5
8
Days Postwounding

Figure 9



1-3 Minimal cell accumulation, no granulation
4-6 Immature granulation, inflammatory cells, capillaries
10-12 Fibroblasts, collagen, epithelium

Figure 10



1-3 Minimal cell accumulation, no granulation
4-6 Immature granulation, inflammatory cells, capillaries
7-9 Granulation tissue, cells, fibroblasts, new epithelium
10-12 Fibroblasts, collagen, epithelium

Figure 11



Anti-cytokeratin Immunostaining
0 - No closure
5 - Slight to moderate closure
10 - Complete closure

Figure 12



Anti-cytokeratin Immunostaining
0 - No closure
5 - Slight to moderate closure
10 - Complete closure

Figure 13



PCNA Scoring
0-2 Slight proliferation
3-5 Moderate proliferation
6-8 Intense proliferation

Figure 14



PCNA Scoring
0-2 Slight proliferation
3-5 Moderate proliferation
6-8 Intense proliferation

Figure 15

ATGAGAGGATCGCATCACCATCACCATCACGGATCCTGCCAGGCTCTGGGTC
AGGACATGGTTTCTCCGGAAGCTACCAACTCTTCCTCTTCCTCTTTCTCTTCCC
CGTCTTCCGCTGGTCGTCACGTTCGTTCTTACAACCACCTGCAGGGTGACGTTC
GTTGGCGTAAACTGTTCTCTTTCACCAAATACTTCCTGAAAATCGAAAAA
AACGGTAAAGTTTCTGGGACCAAGAAGGAGAACTGCCCGTACAGCATCCTG
GAGATAACATCAGTAGAAATCGGAGTTGTTGCCGTCAAAGCCATTAACAG
CAACTATTACTTAGCCATGAACAAGAAGGGGAAACTCTATGGCTCAAAAG
AATTTAACAATGACTGTAAGCTGAAGGAGAGGATAGAGGAAAATGGAT
ACAATACCTATGCATCATTTAACTGGCAGCATAATGGGAGGCAAATGTAT
GTGGCATTGAaTGGAAAAGGAGCTCCAaGGAGAGGACAGAAAACACGAAG
GAAAAACACCTCTGCTCACTTTCTTCCAATGGTGGTACACTCATAG

MRGSHHHHHHGSCQALGQDMVSPEATNSSSSSFSSPSSAGRHVRSYNHLQGD
VRWRKLFSFTKYFLKIEKNGKVSGTKKENCPYSILEITSVEIGVVAVKAINSN
YYLAMNKKGKLYGSKEFNNDCKLKERIEENGYNTYASFNWQHNGRQMYVA
LNGKGAPRRGQKTRRKNTSAHFLPMVVHS

kgf-2 synthetic cys37 Bam HI
AAAGGATCCTGCCAGGCTCTGGGTCAGGACATG

Figure 16



Day 8 Postwounding
Wound Measure area (sq. mm)
65
60
55
50
45
40
35
30
25
20
15
10
5
0
58.4
p=0.002
22.4
47.3
p=0.002
25.5
p=0.005
17.3
No Treatment + Methyl prednisolone
No Treatment
Buffer
KGF-2 1µg
KGF-2 4µg

Figure 17



Glucocorticoid Treated Animals
% Wound Closure
100
95
90
85
80
75
70
65
60
55
50
45
40
35
30
25
20
15
10
5
0
p=0.0008
p=0.002
73.0
60.2
28.6
12.5
No Treatment
Buffer
KGF-2
1µg
KGF-2
4µg

Figure 18



No Treatment
Buffer
KGF-2 1µg
KGF-2 4µg
Wound Closure (sq. mm)
105
100
95
90
85
80
75
70
65
60
55
50
45
40
35
30
25
20
15
10
p=0.04
p=0.03
p=0.03
p=0.005
p=0.0003
p=0.0004
p=0.002
p=0.0005
1
2
3
4
5
8
Days Postwounding

Figure 19A



Wound Measure Area (sq. mm)
55
50
45
40
35
30
25
20
15
10
5
0
48.8
42.3
38.0
p=0.02
31.8
No Treatment
Buffer
KGF-2 1μg
KGF-2 4μg
Day 5 Postwounding

Figure 19B



Day 10 Postwounding

Figure 20



Wound Distance (μ)
6500
6000
5500
5000
4500
4000
3500
3000
2500
2000
1500
1000
500
0
5336
4734
2972
3086
p=0.04
No Treatment
Buffer
KGF-2 1μg
KGF-2 4μg
Glucocorticoid Treated Group

Figure 21A



0.4
0.3
0.2
0.1
0
O.D. 570 nm - 630 nm
KBM
KBM
KGM
KGM
1000
100
30
10
3
1
0.3
0.1
conc. (ng/ml)
KGF2 E3

Figure 21B



0.5
0.4
0.3
0.2
0.1
0
O.D. 570 nm - 630 nm
KBM
KBM
KGM
KGM
1000
100
30
10
3
1
0.3
0.1
conc. (ng/ml)
KGF2 d33 B1large

Figure 21C


O.D. 570 nm - 630 nm
0.5
0.4
0.3
0.2
0.1
0
KBM
KBM
KGM
KGM
1000
100
30
10
3
1
0.3
0.1
conc. (ng/ml)
KGF2 d28 E2

Figure 22A



FGF7
KGF-2
Thymidine incorporation (CPM)
20000
15000
10000
5000
0
0.01
0.1
1
10
[FGF7] (nM)
[KGF-2](nM)

Figure 22B



10000
7500
5000
2500
0
CPM
Media Only
Buffer
.22 ng/ml
2.2 ng/ml
11 ng/ml
22 ng/ml
110 ng/ml
220 ng/ml
HG03401 E3
HG03410 E1
HG03411 E1
HG03411 E2

Figure 22C



CPM
30000
20000
10000
0
3401-E3
delta 28-E1
delta 33-E1
No addition
buffer
0.22ng/ml
2.2ng/ml
11ng/ml
22ng/ml
110ng/ml
220ng/ml

Figure 23

```
ATGTGGAAATGGATACTGACCCACTGCGCTTCTGCTTTCCCGCACCTGCCGGGTTGCTGC  60
Met Trp Lys Trp Ile Leu Thr His Cys Ala Ser Ala Phe Pro His Leu Pro Gly Cys Cys

TGCTGCTGCTTCCTGCTGCTGTTCCTGGTTTCTTCTGTTCCGGTTACCTGCCAGGCTCTG  120
Cys Cys Cys Phe Leu Leu Leu Phe Leu Val Ser Ser Val Pro Val Thr Cys Gln Ala Leu

GGTCAGGACATGGTTTCTCCGGAAGCTACCAACTCTTCCTCTTCCTCTTTCTCTTCCCCG  180
Gly Gln Asp Met Val Ser Pro Glu Ala Thr Asn Ser Ser Ser Ser Ser Phe Ser Ser Pro

ACTTCCGCTGGTCGTCACGTTCGTTCTTACAACCACCTGCAGGGTGACGTTCGTTGGCGT  240
Thr Ser Ala Gly Arg His Val Arg Ser Tyr Asn His Leu Gln Gly Asp Val Arg Trp Arg

AAACTGTTCTCTTTCACCAAATACTTCCTGAAAATCGAAAAAAACGGTAAAGTTTCTGGG  300
Lys Leu Phe Ser Phe Thr Lys Tyr Phe Leu Lys Ile Glu Lys Asn Gly Lys Val Ser Gly

ACCAAGAAGGAGAACTGCCCGTACAGCATCCTGGAGATAACATCAGTAGAAATCGGAGTT  360
Thr Lys Lys Glu Asn Cys Pro Tyr Ser Ile Leu Glu Ile Thr Ser Val Glu Ile Gly Val

GTTGCCGTCAAAGCCATTAACAGCAACTATTACTTAGCCATGAACAAGAAGGGGAAACTC  420
Val Ala Val Lys Ala Ile Asn Ser Asn Tyr Tyr Leu Ala Met Asn Lys Lys Gly Lys Leu

TATGGCTCAAAAGAATTTAACAATGACTGTAAGCTGAAGGAGAGGATAGAGGAAAATGGA  480
Tyr Gly Ser Lys Glu Phe Asn Asn Asp Cys Lys Leu Lys Glu Arg Ile Glu Glu Asn Gly

TACAATACCTATGCATCATTTAACTGGCAGCATAATGGGAGGCAAATGTATGTGGCATTG  540
Tyr Asn Thr Tyr Ala Ser Phe Asn Trp Gln His Asn Gly Arg Gln Met Tyr Val Ala Leu

AATGGAAAAGGAGCTCCAAGGAGAGGACAGAAAACACGAAGGAAAAACACCTCTGCTCAC  600
Asn Gly Lys Gly Ala Pro Arg Arg Gly Gln Lys Thr Arg Arg Lys Asn Thr Ser Ala His

TTTCTTCCAATGGTGGTACACTCATAG 627
Phe Leu Pro Met Val Val His Ser •
```

Figure 24A

ATGACCTGCCAGGCTCTGGGTCAGGACATGGTTTCTCCGGAAGCTACCAACTCTTCCTCT 60
Met Thr Cys Gln Ala Leu Gly Gln Asp Met Val Ser Pro Glu Ala Thr Asn Ser Ser Ser

TCCTCTTTCTCTTCCCCGTCTTCCGCTGGTCGTCACGTTCGTTCTTACAACCACCTGCAG 120
Ser Ser Phe Ser Ser Pro Ser Ser Ala Gly Arg His Val Arg Ser Tyr Asn His Leu Gln

GGTGACGTTCGTTGGCGTAAACTGTTCTCTTTCACCAAATACTTCCTGAAAATCGAAAAA 180
Gly Asp Val Arg Trp Arg Lys Leu Phe Ser Phe Thr Lys Tyr Phe Leu Lys Ile Glu Lys

AACGGTAAAGTTTCTGGGACCAAGAAGGAGAACTGCCCGTACAGCATCCTGGAGATAACA 240
Asn Gly Lys Val Ser Gly Thr Lys Lys Glu Asn Cys Pro Tyr Ser Ile Leu Glu Ile Thr

TCAGTAGAAATCGGAGTTGTTGCCGTCAAAGCCATTAACAGCAACTATTACTTAGCCATG 300
Ser Val Glu Ile Gly Val Val Ala Val Lys Ala Ile Asn Ser Asn Tyr Tyr Leu Ala Met

AACAAGAAGGGGAAACTCTATGGCTCAAAAGAATTTAACAATGACTGTAAGCTGAAGGAG 360
Asn Lys Lys Gly Lys Leu Tyr Gly Ser Lys Glu Phe Asn Asn Asp Cys Lys Leu Lys Glu

AGGATAGAGGAAAATGGATACAATACCTATGCATCATTTAACTGGCAGCATAATGGGAGG 420
Arg Ile Glu Glu Asn Gly Tyr Asn Thr Tyr Ala Ser Phe Asn Trp Gln His Asn Gly Arg

CAAATGTATGTGGCATTGAATGGAAAAGGAGCTCCAAGGAGAGGACAGAAAACACGAAGG 480
Gln Met Tyr Val Ala Leu Asn Gly Lys Gly Ala Pro Arg Arg Gly Gln Lys Thr Arg Arg

AAAAACACCTCTGCTCACTTTCTTCCAATGGTGGTACACTCATAG 525
Lys Asn Thr Ser Ala His Phe Leu Pro Met Val Val His Ser •

Figure 24B

```
ATGACTTGCCAGGCACTGGGTCAAGACATGGTTTCCCCGGAAGCTACCAACAGCTCCAGCTCTAGCTTCA
                                                                        70
TACTGAACGGTCCGTGACCCAGTTCTGTACCAAAGGGGCCTTCGATGGTTGTCGAGGTCGAGATCGAAGT

 M  T  C  Q  A  L  G  Q  D  M  V  S  P  E  A  T  N  S  S  S  S  S  F

GCAGCCCATCTAGCGCAGGTCGTCACGTTCGCTCTTACAACCACTTACAGGGTGATGTTCGTTGGCGCAA
                                                                        140
CGTCGGGTAGATCGCGTCCAGCAGTGCAAGCGAGAATGTTGGTGAATGTCCCACTACAAGCAACCGCGTT

S  S  P  S  S  A  G  R  H  V  R  S  Y  N  H  L  Q  G  D  V  R  W  R  K

ACTGTTCAGCTTTACCAAGTACTTCCTGAAAATCGAAAAAAACGGTAAAGTTTCTGGGACCAAGAAGGAG
                                                                        210
TGACAAGTCGAAATGGTTCATGAAGGACTTTTAGCTTTTTTTGCCATTTCAAAGACCCTGGTTCTTCCTC

 L  F  S  F  T  K  Y  F  L  K  I  E  K  N  G  K  V  S  G  T  K  K  E

AACTGCCCGTACAGCATCCTGGAGATAACATCAGTAGAAATCGGAGTTGTTGCCGTCAAAGCCATTAACA
                                                                        280
TTGACGGGCATGTCGTAGGACCTCTATTGTAGTCATCTTTAGCCTCAACAACGGCAGTTTCGGTAATTGT

 N  C  P  Y  S  I  L  E  I  T  S  V  E  I  G  V  V  A  V  K  A  I  N

GCAACTATTACTTAGCCATGAACAAGAAGGGGAAACTCTATGGCTCAAAAGAATTTAACAATGACTGTAA
                                                                        350
CGTTGATAATGAATCGGTACTTGTTCTTCCCCTTTGAGATACCGAGTTTTCTTAAATTGTTACTGACATT

S  N  Y  Y  L  A  M  N  K  K  G  K  L  Y  G  S  K  E  F  N  N  D  C  K

GCTGAAGGAGAGGATAGAGGAAAATGGATACAATACCTATGCATCATTTAACTGGCAGCATAATGGGAGG
                                                                        420
CGACTTCCTCTCCTATCTCCTTTTACCTATGTTATGGATACGTAGTAAATTGACCGTCGTATTACCCTCC

 L  K  E  R  I  E  E  N  G  Y  N  T  Y  A  S  F  N  W  Q  H  N  G  R

CAAATGTATGTGGCATTGAATGGAAAAGGAGCTCCAAGGAGAGGACAGAAAACACGAAGGAAAAACACCT
                                                                        490
GTTTACATACACCGTAACTTACCTTTTCCTCGAGGTTCCTCTCCTGTCTTTTGTGCTTCCTTTTTGTGGA

 Q  M  Y  V  A  L  N  G  K  G  A  P  R  R  G  Q  K  T  R  R  K  N  T

CTGCTCACTTTCTTCCAATGGTGGTACACTCATAG
                                    525
GACGAGTGAAAGAAGGTTACCACCATGTGAGTATC

S  A  H  F  L  P  M  V  V  H  S  .
```

Figure 25

ATGACCTGCCAGGCTCTGGGTCAGGACATGGTTTCTCCGGAAGCTACCAACTCTTCC
TCTTCCTCTTTCTCTTCCCCGTCTTCCGCTGGTCGTCACGTTCGTTCTTACAACCACCT
GCAGGGTGACGTTCGTTGGCGTAAACTGTTCTCTTTCACCAAATACTTCCTGAAAAT
CGAAAAAAACGGTAAAGTTTCTGGGACCAAGAAGGAGAACTGCCCGTACAGCATCC
TGGAGATAACATCAGTAGAAATCGGAGTTGTTGCCGTCAAAGCCATTAACAGCAAC
TATTACTTAGCCATGAACAAGAAGGGGAAACTCTATGGCTCAAAAGAATTTAACAA
TGACTGTAAGCTGAAGGAGAGGATAGAGGAAAATGGATACAATACCTATGCATCAT
TTAACTGGCAGCATAATGGGAGGCAAATGTATGTGGCATTGAATGGAAAAGGAGCT
CCAAGGAGAGGACAGAAAACACGAAGGAAAAACACCTCTGCTCACTTTCTTCCAAT
GGTGGTACACTCATAG

MTCQALGQDMVSPEATNSSSSSFSSPSSAGRHVRSYNHLQGDVRWRKLFSFTKYFLKIE
KNGKVSGTKKENCPYSILEITSVEIGVVAVKAINSNYYLAMNKKGKLYGSKEFNNDCKL
KERIEENGYNTYASFNWQHNGRQMYVALNGKGAPRRGQKTRRKNTSAHFLPMVVHS.

Figure 26

ATGGCTGGTCGTCACGTTCGTTCTTACAACCACCTGCAGGGTGACGTTCGTTGGCGT
AAACTGTTCTCTTTCACCAAATACTTCCTGAAAATCGAAAAAAACGGTAAAGTTTCT
GGGACCAAGAAGGAGAACTGCCCGTACAGCATCCTGGAGATAACATCAGTAGAAAT
CGGAGTTGTTGCCGTCAAAGCCATTAACAGCAACTATTACTTAGCCATGAACAAGAA
GGGGAAACTCTATGGCTCAAAAGAATTTAACAATGACTGTAAGCTGAAGGAGAGGA
TAGAGGAAAATGGATACAATACCTATGCATCATTTAACTGGCAGCATAATGGGAGG
CAAATGTATGTGGCATTGAATGGAAAAGGAGCTCCAAGGAGAGGACAGAAAACAC
GAAGGAAAAACACCTCTGCTCACTTTCTTCCAATGGTGGTACACTCATAG

MAGRHVRSYNHLQGDVRWRKLFSFTKYFLKIEKNGKVSGTKKENCPYSILEITSVEIGV
VAVKAINSNYYLAMNKKGKLYGSKEFNNDCKLKERIEENGYNTYASFNWQHNGRQMY
VALNGKGAPRRGQKTRRKNTSAHFLPMVVHS.

Figure 27

ATGGTTCGTTGGCGTAAACTGTTCTCTTTCACCAAATACTTCCTGAAAATCGAAAAA
AACGGTAAAGTTTCTGGGACCAAGAAGGAGAACTGCCCGTACAGCATCCTGGAGAT
AACATCAGTAGAAATCGGAGTTGTTGCCGTCAAAGCCATTAACAGCAACTATTACTT
AGCCATGAACAAGAAGGGGAAACTCTATGGCTCAAAAGAATTTAACAATGACTGTA
AGCTGAAGGAGAGGATAGAGGAAAATGGATACAATACCTATGCATCATTTAACTGG
CAGCATAATGGGAGGCAAATGTATGTGGCATTGAATGGAAAAGGAGCTCCAAGGAG
AGGACAGAAAACACGAAGGAAAAACACCTCTGCTCACTTTCTTCCAATGGTGGTAC
ACTCATAG

MVRWRKLFSFTKYFLKIEKNGKVSGTKKENCPYSILEITSVEIGVVAVKAINSNYYLAM
NKKGKLYGSKEFNNDCKLKERIEENGYNTYASFNWQHNGRQMYVALNGKGAPRRGQ
KTRRKNTSAHFLPMVVHS.

Figure 28

ATGGAAAAAAACGGTAAAGTTTCTGGGACCAAGAAGGAGAACTGCCCGTACAGCAT
CCTGGAGATAACATCAGTAGAAATCGGAGTTGTTGCCGTCAAAGCCATTAACAGCA
ACTATTACTTAGCCATGAACAAGAAGGGGAAACTCTATGGCTCAAAAGAATTTAAC
AATGACTGTAAGCTGAAGGAGAGGATAGAGGAAAATGGATACAATACCTATGCATC
ATTTAACTGGCAGCATAATGGGAGGCAAATGTATGTGGCATTGAATGGAAAAGGAG
CTCCAAGGAGAGGACAGAAAACACGAAGGAAAAACACCTCTGCTCACTTTCTTCCA
ATGGTGGTACACTCATAG

MEKNGKVSGTKKENCPYSILEITSVEIGVVAVKAINSNYYLAMNKKGKLYGSKEFNNDC
KLKERIEENGYNTYASFNWQHNGRQMYVALNGKGAPRRGQKTRRKNTSAHFLPMVVH
S.

Figure 29

ATGGAGAACTGCCCGTACAGCATCCTGGAGATAACATCAGTAGAAATCGGAGTTGT
TGCCGTCAAAGCCATTAACAGCAACTATTACTTAGCCATGAACAAGAAGGGGAAAC
TCTATGGCTCAAAAGAATTTAACAATGACTGTAAGCTGAAGGAGAGGATAGAGGAA
AATGGATACAATACCTATGCATCATTTAACTGGCAGCATAATGGGAGGCAAATGTA
TGTGGCATTGAATGGAAAAGGAGCTCCAAGGAGAGGACAGAAAACACGAAGGAAA
AACACCTCTGCTCACTTTCTTCCAATGGTGGTACACTCATAG

MENCPYSILEITSVEIGVVAVKAINSNYYLAMNKKGKLYGSKEFNNDCKLKERIEENGY
NTYASFNWQHNGRQMYVALNGKGAPRRGQKTRRKNTSAHFLPMVVHS.

Figure 30

ATGGTCAAAGCCATTAACAGCAACTATTACTTAGCCATGAACAAGAAGGGGAAACT
CTATGGCTCAAAAGAATTTAACAATGACTGTAAGCTGAAGGAGAGGATAGAGGAAA
ATGGATACAATACCTATGCATCATTTAACTGGCAGCATAATGGGAGGCAAATGTATG
TGGCATTGAATGGAAAAGGAGCTCCAAGGAGAGGACAGAAAACACGAAGGAAAAA
CACCTCTGCTCACTTTCTTCCAATGGTGGTACACTCATAG

MVKAINSNYYLAMNKKGKLYGSKEFNNDCKLKERIEENGYNTYASFNWQHNGRQMY
VALNGKGAPRRGQKTRRKNTSAHFLPMVVHS.

Figure 31

ATGGGGAAACTCTATGGCTCAAAAGAATTTAACAATGACTGTAAGCTGAAGGAGAG
GATAGAGGAAAATGGATACAATACCTATGCATCATTTAACTGGCAGCATAATGGGA
GGCAAATGTATGTGGCATTGAATGGAAAAGGAGCTCCAAGGAGAGGACAGAAAAC
ACGAAGGAAAAACACCTCTGCTCACTTTCTTCCAATGGTGGTACACTCATAG

MGKLYGSKEFNNDCKLKERIEENGYNTYASFNWQHNGRQMYVALNGKGAPRRGQKT
RRKNTSAHFLPMVVHS.

Figure 32

ATGACCTGCCAGGCTCTGGGTCAGGACATGGTTTCTCCGGAAGCTACCAACTCTTCC
TCTTCCTCTTTCTCTTCCCCGTCTTCCGCTGGTCGTCACGTTCGTTCTTACAACCACCT
GCAGGGTGACGTTCGTTGGCGTAAACTGTTCTCTTTCACCAAATACTTCCTGAAAAT
CGAAAAAAACGGTAAAGTTTCTGGGACCAAGAAGGAGAACTGCCCGTACAGCATCC
TGGAGATAACATCAGTAGAAATCGGAGTTGTTGCCGTCAAAGCCATTAACAGCAAC
TATTACTTAGCCATGAACAAGAAGGGGAAACTCTATGGCTCAAAAGAATTTAACAA
TGACTGTAAGCTGAAG

MTCQALGQDMVSPEATNSSSSSFSSPSSAGRHVRSYNHLQGDVRWRKLFSFTKYFLKIE
KNGKVSGTKKENCPYSILEITSVEIGVVAVKAINSNYYLAMNKKGKLYGSKEFNNDCKL
K

Figure 33

ATGGCTGGTCGTCACGTTCGTTCTTACAACCACCTGCAGGGTGACGTTCGTTGGCGT
AAACTGTTCTCTTTCACCAAATACTTCCTGAAAATCGAAAAAAACGGTAAAGTTTCT
GGGACCAAGAAGGAGAACTGCCCGTACAGCATCCTGGAGATAACATCAGTAGAAAT
CGGAGTTGTTGCCGTCAAAGCCATTAACAGCAACTATTACTTAGCCATGAACAAGAA
GGGGAAACTCTATGGCTCAAAAGAATTTAACAATGACTGTAAGCTGAAG

MAGRHVRSYNHLQGDVRWRKLFSFTKYFLKIEKNGKVSGTKKENCPYSILEITSVEIGV
VAVKAINSNYYLAMNKKGKLYGSKEFNNDCKLK

Figure 34

C-37 To Ser

ATGACCTCTCAGGCTCTGGGTCAGGACATGGTTTCTCCGGAAGCTACCAACTCTTCC
TCTTCCTCTTTCTCTTCCCCGTCTTCCGCTGGTCGTCACGTTCGTTCTTACAACCACCT
GCAGGGTGACGTTCGTTGGCGTAAACTGTTCTCTTTCACCAAATACTTCCTGAAAAT
CGAAAAAAACGGTAAAGTTTCTGGGACCAAGAAGGAGAACTGCCCGTACAGCATCC
TGGAGATAACATCAGTAGAAATCGGAGTTGTTGCCGTCAAAGCCATTAACAGCAAC
TATTACTTAGCCATGAACAAGAAGGGGAAACTCTATGGCTCAAAAGAATTTAACAA
TGACTGTAAGCTGAAGGAGAGGATAGAGGAAAATGGATACAATACCTATGCATCAT
TTAACTGGCAGCATAATGGGAGGCAAATGTATGTGGCATTGAATGGAAAAGGAGCT
CCAAGGAGAGGACAGAAAACACGAAGGAAAAACACCTCTGCTCACTTTCTTCCAAT
GGTGGTACACTCATAG

Figure 35

C-106 To Ser

ATGACCTGCCAGGCTCTGGGTCAGGACATGGTTTCTCCGGAAGCTACCAACTCTTCC
TCTTCCTCTTTCTCTTCCCCGTCTTCCGCTGGTCGTCACGTTCGTTCTTACAACCACCT
GCAGGGTGACGTTCGTTGGCGTAAACTGTTCTCTTTCACCAAATACTTCCTGAAAAT
CGAAAAAAACGGTAAAGTTTCTGGGACCAAGAAGGAGAACTCTCCGTACAGCATCC
TGGAGATAACATCAGTAGAAATCGGAGTTGTTGCCGTCAAAGCCATTAACAGCAAC
TATTACTTAGCCATGAACAAGAAGGGGAAACTCTATGGCTCAAAAGAATTTAACAA
TGACTGTAAGCTGAAGGAGAGGATAGAGGAAAATGGATACAATACCTATGCATCAT
TTAACTGGCAGCATAATGGGAGGCAAATGTATGTGGCATTGAATGGAAAAGGAGCT
CCAAGGAGAGGACAGAAAACACGAAGGAAAAACACCTCTGCTCACTTTCTTCCAAT
GGTGGTACACTCATAG

Figure 36



Wound Area (sq. mm)
45
40
35
30
25
20
15
1
2
3
4
5
Days Post-wounding
No Treatment
Buffer
KGF-2 0.1µg
KGF-2 0.4µg
KGF-2 1µg
KGF-2 4µg
*p=0.007
*p=0.006
p=0.04
p=0.02
p=0.04
*p=0.02

Figure 37

Effect of KGF-2 Δ33 on Normal Wound Healing Rat Model

Treatment Groups	Wound Size (mm)	%Wound Closure	Histological Score	Re-epith. (µm)	BrdU Score
No Treatment	25.9 ± 2.5	58.8 ± 3.7	6.8 ± 0.2	1142 ± 141	3.8 ± 0.4
Buffer	25.1 ± 1.7	60.2 ± 2.6	6.4 ± 0.2	923 ± 61	5.0 ± 0.4
KGF-2/Δ33 (0.1µg)	22.0 ± 0.9	65 ± 1.4	6.8 ± 0.2	1275 ± 148	4.6 ± 0.7
KGF-2/Δ33 (0.4 µg)	21.1 ± 1.4	68.4 ± 2.4	8.0 ± 0.5 p=0.0445*	1310 ± 182	4.2 ± 0.7
KGF-2/Δ33 (1.0µg)	19.9 ± 1.5	66.2 ± 2.1	8.4 ± 0.4 p=0.0159* p=0.0053†	1389 ± 115 p=0.0074†	3.3 ± 0.25 p=0.0217†
KGF-2/Δ33 (4.0µg)	18.1 ± 1.6 p=0.0398* p=0.0200†	71.2 ± 2.6 p=0.0367* p=0.0217†	8.5 ± 0.3 p=0.0047* p=0.0445†	1220 ± 89 p=0.0254†	5.3 ± 0.9

Figure 38


Breaking Strength (g)
140
130
120
110
100
90
80
70
60
50
40
30
20
10
0
p=0.0006
p<0.0001
p<0.0001
44.5
107.3
126.4
123.8
Buffer
KGF-2 1 µg
KGF-2 4 µg
KGF-2 10 µg
n=8
n=8
n=9
n=8

Figure 39



p=0.01
Epidermal Thickness (μ)
70
65
60
55
50
45
40
35
30
25
20
15
10
5
0
54.8
60.5
66.5
59.6
Buffer
KGF-2 1 μg
KGF-2 4 μg
KGF-2 10 μg

Figure 40



45
44
43
42
41
40
39
38
37
36
35
34
33
32
31
30
29
28
27
26
25
Buffer
KGF-2 1μg
KGF-2 4μg
p<0.0001
p<0.0001
p<0.0001
p=0.0003
Epidermal Thickness (μ)
24
48
Hours Post Injection

Figure 41



BrdU Score
8
7
6
5
4
3
2
1
0
p<0.0001
p=0.007
5.0
3.9
5.2
3.3
4.7
6.9
Buffer
KGF-2 1µg
KGF-2 4µg
Buffer
KGF-2 1µg
KGF-2 4µg
24 Hours
48 Hours

Figure 42

No.1



No.2



Effect of KGF-2 Δ33 on PAF-induced paw edema in Lewis rats



Figure 43

Effect of KGF-2 Δ33 on Survival of Whole Body Irradiated Balb/c Mice



Figure 44

Effect of KGF-2 Δ33 on Body Weight of Irradiated Mice



Figure 45



KGF-2 Δ33 (1 mg/kg)
KGF-2 Δ33 (5 mg/kg)
Buffer
Percent Survival
100
90
80
70
60
50
40
30
20
10
0
0
5
10
15
20
25
Days Post Irradiation

Figure 46



60
50
40
30
20
10
0
Wound Measure Area (mm)
No Treatment
Buffer
KGF-2 0.1µg
KGF-2 0.5µg
KGF-2 1.5µg
p<0.0001
*p=0.0003
p=0.0002
*p=0.005
p=0.001
*p=0.02
Day 8 Postwounding

Figure 47

Figure 48



p=0.005
p=0.01
BrdU Score
6
5
4
3
2
1
0
3.4
3.6
4.0
4.5
5.2
No Treatment
Buffer
KGF-2 0.1 µg
KGF-2 1 µg
KGF-2 10 µg


p=0.0299
p=0.0045
Collagen (µg/mg tissue)
30
25
20
15
10
5
0
6.3
n=9
10.6
n=9
23.6
n=8
18.2
n=8
No Treatment
Buffer
KGF-2 1 mg/kg
KGF-2 5 mg/kg

Figure 49


Hind III
Nde I
Pvu II
Bgl II
Asp 718
EcoR I
Pst I
Pvu II
KGF-2
Pvu II
kan
pHE4-5
KGF-2
Pvu II
Pst I
Sal I
Pvu II
Pvu II
Sal I
lacI

FIGURE 50

FIGURE 51

-35 / Operator 1

1 *AAGCTT* AAAAAACTGCAAAAAATAGT TTGACT TGTGAGCGGATAACAAT

-10 / Operator 2

50 TAAGAT GTACCCA ATTGTGAGCGGATAACAAT TTCACACATTAA

S/D

94 A GAGGAG AAATTA *CATATG*



25
20
15
10
5
0
% proliferation
0
2
4
6
8
Time (days)
KGF-2; sc
Buffer; sc
KGF-2; ip
Buffer; ip

FIGURE 52


125
100
75
50
25
0
proliferating cells/field
0
2
4
6
8
Time (days)
KGF-2; sc
Buffer; sc
KGF-2; ip
Buffer; ip

FIGURE 53


50
40
30
20
10
0
Percent Ulceration
p=0.0338
p=0.0128
Saline Control
Buffer
KGF-2 1 mg/kg
KGF-2 5 mg/kg

FIGURE 54


250
200
150
100
50
0
Bladder Wall Thickness
p=0.0077
p<0.0001
Saline Control
Buffer
KGF-2 1 mg/kg
KGF-2 5 mg/kg

FIGURE 55


Daily injections
Treatment-free
KGF-2 (5 mg/kg)
or buffer
Time (days)
0
1
2
3
6
7
15
sacrifice
sacrifice
sacrifice

FIGURE 56

Proliferation of hepatocytes following systemic administration of KGF-2



FIGURE 57

Proliferation of pancreatic cells following systemic administration of KGF-2



FIGURE 58

Proliferation of renal epithelia after systemic administration of KGF-2



FIGURE 59



BrdU Positive Cells/Field
30
20
10
0
p=0.0002
p= 0.0003
No Treatment
Buffer
KGF-2 1mg/kg
KGF-2 5mg/kg

FIGURE 60